| Autor: |
Marianne Martinello, Sanjay Bhagani, David Shaw, Chloe Orkin, Graham Cooke, Edward Gane, David Iser, Andrew Ustianowski, Ranjababu Kulasegaram, Catherine Stedman, Elise Tu, Jason Grebely, Gregory J. Dore, Mark Nelson, Gail V. Matthews |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
JHEP Reports, Vol 5, Iss 10, Pp 100867- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2589-5559 |
| DOI: |
10.1016/j.jhepr.2023.100867 |
| Popis: |
Background & Aims: Short duration treatment may aid HCV elimination among key populations. This study evaluated the efficacy of glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection. Methods: In this single-arm multicentre international trial, adults with recent HCV (duration of infection 10x the upper limit of normal) or antibody seroconversion within 18 months. Reinfection was defined as new positive HCV RNA within 6 months and prior clearance (spontaneous or treatment). The primary endpoint was sustained virological response at 12 weeks post-treatment (SVR12) in the intention-to-treat (ITT) and per-protocol (PP) populations. Results: Twenty-three participants (96% men, 70% HIV, 57% ever injected drugs) received treatment, of whom 74% had genotype 1a infection and 35% recent reinfection. At baseline, median duration of infection was 17 weeks (IQR 11–29) and HCV RNA was 5.8 log10IU/ml (IQR 5.2–6.9). SVR12 was achieved by 78% (18/23; 95% CI 56–93%) and 82% (18/22; 95% CI 60–95%) of the ITT and PP populations, respectively, and in 100% (12/12; 95% CI 74–100%) of participants with baseline HCV RNA ≤6 log10. There were four cases of virological failure (relapse); three received retreatment with 12 weeks sofosbuvir-velpatasvir or grazoprevir-elbasvir (SVR, n = 2; loss to follow-up, n = 1). No serious adverse events were reported. Conclusion: While most achieved SVR, the efficacy of a 4-week regimen of glecaprevir-pibrentasvir was lower than observed with longer treatment durations (≥6 weeks) among people with recent HCV. Trial Registration: Clinicaltrials.gov Identifier: NCT02634008. Impact and implications: Short duration treatment may aid HCV elimination among key populations. This investigator-initiated single-arm multicentre international pilot trial demonstrated that efficacy of glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection was sub-optimal (SVR12 78% ITT, 82% PP). Baseline HCV RNA appeared to impact response, with higher efficacy among participants with lower baseline HCV RNA (≤6 log10; SVR12 100% ITT, 12/12). While most achieved SVR, the efficacy of 4 weeks of glecaprevir-pibrentasvir was below that seen with longer treatment durations (≥6 weeks). |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
